Toggle Side Panel
Close search

Esketamine in depression

Esketamine represents one of the most significant developments in biological psychiatry in recent decades.

This article has been allocated 0.5 EA by the RACGP and ACRRM for the 2026-2028 triennium.

You can self-report this CPD/PDP activity by logging it online with the RACGP and ACRRM. Click on the link for RACGP Quick Log or go to your ACRRM page.

Need to know

Treatment-resistant depression remains one of the greatest challenges in contemporary psychiatry. Treatment-resistant depression is commonly defined as an inadequate response to trials of at least two antidepressants of adequate dose and duration from different pharmacological classes.1

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Content that breaches the privacy of other individuals
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .